問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Others-

Division of Hematology & Oncology

Division of General Internal Medicine

National Taiwan University Hospital Bei-Hu Branch  (在職)

Division of Hematology & Oncology

更新時間：2023-09-19

徐思淳
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

28Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

徐思淳

List

57Cases

2010-09-30 - 2012-08-31

Phase IV

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2012-11-01 - 2017-03-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2014-03-19 - 2016-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2020-11-30 - 2025-05-27

Phase III

An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial

  • Condition/Disease

    Chronic Lymphocytic Leukemia

  • Test Drug

    Venetoclax

Participate Sites
2Sites

Recruiting1Sites

Terminated1Sites

2018-03-01 - 2020-05-31

Phase III

ATLAS-A/B: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients With Hemophilia A or B, Without Inhibitory Antibodies to Factor VIII or IX

  • Condition/Disease

    Hemophilia A or B

  • Test Drug

    Fitusiran (ALN-AT3SC)

Participate Sites
7Sites

Not yet recruiting1Sites

Recruiting6Sites

張家堯
Taipei Medical University Hospital

Division of Pediatrics

2011-10-01 - 2015-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2007-06-01 - 2008-06-30

Others

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2016-03-31 - 2021-12-31

Phase III

A randomized, double blind, placebo-controlled, multi-center, Phase III study investigating the efficacy and safety of ruxolitinib in Early Myelofibrosis patients with high molecular risk mutations

  • Condition/Disease

    Early Myelofibrosis

  • Test Drug

    JAKAVI

Participate Sites
3Sites

Terminated3Sites

2015-06-01 - 2017-09-30

Phase II

A multi-center, randomized, double-blind, placebo controlled, study to evaluate the efficacy and safety of CSJ148 compared to placebo to prevent human cytomegalovirus (HCMV) replication in stem cell transplant patients

  • Condition/Disease

    prevent human cytomegalovirus (HCMV) replication in stem cell transplant patients

  • Test Drug

    CSJ148

Participate Sites
4Sites

Terminated3Sites

2007-07-01 - 2019-10-24

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

1 2 3 4 5 6
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB